Efficacy of Tyverb in combination with capecitabine
In second-line HER2+ metastatic breast cancer, Tyverb in combination with capecitabine has been proven effective for patients who have had prior therapy with anthracycline, taxanes, and trastuzumab
The clinical efficacy of Tyverb in the treatment of HER2-positive (HER2+) advanced/metastatic breast cancer was first demonstrated in the EGF100151 study.1,2
Women enrolled in this trial had HER2+ locally advanced or metastatic breast cancer that had progressed after treatment with regimens that included an anthracycline, a taxane and trastuzumab.
The results of this pivotal phase III clinical trial demonstrated that Tyverb, given in combination with the chemotherapy agent capecitabine, significantly extended the primary clinical endpoint of time to progression (TTP)* to a median of 23.9 weeks compared with treatment with capecitabine monotherapy which achieved a median of 18.3 weeks.2
Effect of Tyverb in combination with capecitabine on time to progression
The median TTP*, assessed by an independent review committee, was 23.9 weeks in the Tyverb plus capecitabine group versus 18.3 weeks in the capecitabine alone group. The combination of Tyverb and capecitabine led to a significant 43% reduction in the risk of progression compared with capecitabine monotherapy (hazard ratio: 0.57, 95% confidence interval [CI] 0.43–0.77; p=0.00013).2
Adapted from Cameron D, Casey M, Press M, et al. Breast Cancer Res Treat. 2008;112:533–543.
Further information on the EGF100151 study can be found in the clinical evidence section.
*TTP defined as the time from randomisation to disease progression or death due to breast cancer.